Fortrea Holdings (FRA:K67) Insider Ownership : 0.00 % (As of Jun. 20, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Fortrea Holdings's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Fortrea Holdings's Institutional Ownership is 59.21%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Fortrea Holdings's Float Percentage Of Total Shares Outstanding is 69.22%.

Fortrea Holdings Insider Ownership Historical Data

The historical data trend for Fortrea Holdings's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings Insider Ownership Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Insider Ownership

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Insider Ownership	Get a 7-Day Free Trial						-	-	-	-	-

Fortrea Holdings Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Fortrea Holdings (FRA:K67) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

FTRE:USA FTRE1:Mexico

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings (FRA:K67) Headlines

No Headlines